Skip to Content
Merck
All Photos(1)

Key Documents

View All Documentation

S5814

Sigma-Aldrich

Stop Reagent for TMB Substrate

chromogenic, powder

Synonym(s):

TMB liquid substrate system stop reagent

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

UNSPSC Code:
12352204
NACRES:
NA.83

product name

Stop Reagent for TMB Substrate, powder, ELISA, 450 nm

form

powder

storage temp.

room temp

General description

Stop Reagent for TMB Substrate is used to stop TMB substrate reaction for ELISA and change the absorbance from blue (620 nm) to yellow (450 nm).

Application

Stop Reagent for TMB Substrate has been used:
  • for in vitro preparation and analysis of neutrophil extracellular traps (NETs)
  • for direct binding enzyme linked immune sorbent assay (ELISA)
  • for interference assay

Pictograms

CorrosionExclamation mark
GHS05,GHS07

Signal Word

Danger

Hazard Classifications

Acute Tox. 4 Dermal - Acute Tox. 4 Oral - Eye Dam. 1 - Skin Corr. 1 - Skin Sens. 1 - STOT SE 3

Target Organs

Respiratory system

Storage Class Code

8A - Combustible corrosive hazardous materials

WGK

WGK 3

Flash Point(F)

260.6 °F - closed cup

Flash Point(C)

127 °C - closed cup

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Fresthel Monica M Climacosa et al.
Protein and peptide letters, 27(10), 962-970 (2020-04-29)
Microbe-Binding Peptides (MBPs) are currently being investigated to address the problem of antimicrobial resistance. Strategies enhancing their antimicrobial activity have been developed, including peptide dimerization. Here, we present an alternative approach based on peptide polymerization, yielding hapten-labelled polymeric MBPs that
Marília Santini-Oliveira et al.
Vaccines, 10(10) (2022-10-28)
We report the successful closure of Phase I clinical trials, comprising Phases Ia and Ib, of the vaccine candidate against human schistosomiasis: the Schistosoma mansoni 14 kDa fatty acid-binding protein (Sm14) + glucopyranosyl lipid A in squalene emulsion (GLA-SE). Shown
Development of a reliable assay to measure glypican-1 in plasma and serum reveals circulating glypican-1 as a novel prostate cancer biomarker
Levin RA, et al.
Oncotarget, 9(32), 22359-22359 (2018)
Prevalence of interfering antibodies in dogs and cats evaluated using a species-independent assay
Bergman D, et al.
Veterinary Clinical Pathology / American Society For Veterinary Clinical Pathology, 47(2), 205-212 (2018)
Myeloid-specific deletion of peptidylarginine deiminase 4 (PAD4) mitigates atherosclerosis.
Liu Y, et al.
Frontiers in Immunology, 9, 1680-1680 (2018)
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service